Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization

References

• Adherence to long-term therapies: evidence for action. World Health Organization; 2003. Available from: https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf. Accessed April 5, 2023.
   Google Scholar
• Lee S, Jiang L, Dowdy D, Hong YA, Ory MG. Attitudes, beliefs, and cost-related medication nonadherence among adults aged 65 or older with chronic diseases. Prev Chronic Dis. 2018;15:E148.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196–201.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134.
   PubMed Web of Science ®Google Scholar
• Jawad I, Watson S, Haddad PM, Talbot PS, McAllister-Williams RH. Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol. 2018;8(12):349–363.
   PubMed Web of Science ®Google Scholar
• Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17.
   PubMed Web of Science ®Google Scholar
• Ho SC, Jacob SA, Tangiisuran B. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS One. 2017;12(6):e0179290.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
   PubMedGoogle Scholar
• Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord. 2016;193:1–10. doi:10.1016/j.jad.2015.12.029
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5). doi:10.4088/JCP.IN18031AH1C
   Web of Science ®Google Scholar
• Desalegn D, Girma S, Abdeta T. Quality of life and its association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. Health Qual Life Outcomes. 2020;18(1):82.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Kane JM. Addressing patients’ unmet needs to improve outcomes in schizophrenia. J Clin Psychiatry. 2021;82(3):63.
   Web of Science ®Google Scholar
• Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. J Manag Care Spec Pharm. 2021;27(2):223–239.
   PubMed Web of Science ®Google Scholar
• Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol. 2011;26(3):173–180.
   PubMed Web of Science ®Google Scholar
• Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res. 2011;190(1):110–114.
   PubMed Web of Science ®Google Scholar
• Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982.
   PubMed Web of Science ®Google Scholar
• Forma F, Green T, Kim S, Teigland C. Antipsychotic medication adherence and healthcare services utilization in two cohorts of patients with serious mental illness. Clinicoecon Outcomes Res. 2020;12:123–132.
   PubMed Web of Science ®Google Scholar
• Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44.
   PubMedGoogle Scholar
• Shafrin J, May SG, Shrestha A, et al. Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers. Patient Prefer Adherence. 2017;11:1071–1081.
   PubMed Web of Science ®Google Scholar
• Girling C, Packham A, Robinson L, Arden MA, Hind D, Wildman MJ. Implementing the use of objective medication adherence data in routine clinical practice via the digital CFHealthHub platform: situation analysis and strategy development using the theoretical domains framework. Implement Sci Commun. 2022;3(1):12.
   PubMedGoogle Scholar
• Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2–3):129–133.
   PubMed Web of Science ®Google Scholar
• Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–482.
   PubMed Web of Science ®Google Scholar
• Martin KB. Accuracy of psychiatrists’ assessment of medication adherence in an outpatient setting. Cureus. 2020;12(12):e11847.
   PubMed Web of Science ®Google Scholar
• Wouters H, Rhebergen D, Vervloet M, et al. Distinct profiles on subjective and objective adherence measures in patients prescribed antidepressants. Drugs. 2019;79(6):647–654.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Schwartz TT, Lakdawalla DN, Forma FM. Estimating the value of new technologies that provide more accurate drug adherence information to providers for their patients with schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1285–1291.
   PubMed Web of Science ®Google Scholar
• Stirratt MJ, Curtis JR, Danila MI, Hansen R, Miller MJ, Gakumo CA. Advancing the science and practice of medication adherence. J Gen Intern Med. 2018;33(2):216–222.
   PubMed Web of Science ®Google Scholar
• Steinkamp JM, Goldblatt N, Borodovsky JT, et al. Technological interventions for medication adherence in adult mental health and substance use disorders: a systematic review. JMIR Ment Health. 2019;6(3):e12493.
   PubMed Web of Science ®Google Scholar
• Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. Eur Psychiatry. 2012;27(1):9–18.
   PubMed Web of Science ®Google Scholar
• Fowler JC, Cope N, Knights J, et al. Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. BMJ Open. 2019;9(6):e025952.
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Profit D, Hatch A, Zhao C, Docherty JP, Peters-Strickland TS. Optimization of a digital medicine system in psychiatry. J Clin Psychiatry. 2016;77(9):e1101–e1107.
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Co, Ltd. Abilify MyCite® (aripiprazole tablets with sensor), for oral use [prescribing information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2022. Available from: https://www.otsuka-us.com/sites/g/files/qhldwo7076/files/media/static/ABILIFY-MYCITE-PI.pdf. Accessed June 1, 2023.
   Google Scholar
• Fowler JC, Cope N, Knights J, et al. Hummingbird Study: results from an exploratory trial assessing the performance and acceptance of a digital medicine system in adults with schizophrenia, schizoaffective disorder, or first-episode psychosis. Neuropsychiatr Dis Treat. 2021;17:483–492.
   PubMed Web of Science ®Google Scholar
• Cochran JM, Fang H, Le Gallo C, Peters-Strickland T, Lindenmayer JP, Reuteman-Fowler JC. Participant engagement and symptom improvement: aripiprazole tablets with sensor for the treatment of schizophrenia. Patient Prefer Adherence. 2022;16:1805–1817.
   PubMed Web of Science ®Google Scholar
• Cochran JM, Fang H, Sonnenberg JG, Cohen EA, Lindenmayer JP, Reuteman-Fowler JC. Healthcare provider engagement with a novel dashboard for tracking medication ingestion: impact on treatment decisions and clinical assessments for adults with schizophrenia. Neuropsychiatr Dis Treat. 2022;18:1521–1534.
   PubMed Web of Science ®Google Scholar
• Cohen EA, Skubiak T, Hadzi Boskovic D, et al. Phase 3b multicenter, prospective, open-label trial to evaluate the effects of a digital medicine system on inpatient psychiatric hospitalization rates for adults with schizophrenia. J Clin Psychiatry. 2022;83(3):46.
   Web of Science ®Google Scholar
• Alipour A, Gabrielson S, Patel PB. Ingestible sensors and medication adherence: focus on use in serious mental illness. Pharmacy. 2020;8(2):5867.
   Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):69–80.
   PubMed Web of Science ®Google Scholar
• Chen JW, Maldonado DR, Kowalski BL, et al. Best practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. A Review. Arthroscopy. 2022;38(2):632–642.
   PubMed Web of Science ®Google Scholar
• Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–161.
   PubMed Web of Science ®Google Scholar
• Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092–1097.
   PubMed Web of Science ®Google Scholar
• Feng CX. A comparison of zero-inflated and hurdle models for modeling zero-inflated count data. J Stat Distrib Appl. 2021;8(1):8.
   PubMedGoogle Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar i disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612–1625.
   PubMed Web of Science ®Google Scholar
• Gauthier G, Guerin A, Zhdanava M, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222.
   PubMedGoogle Scholar
• Joe S, Lee JS. Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders. BMC Psychiatry. 2016;16(1):444.
   PubMedGoogle Scholar
• Mickelson RS, Holden RJ. Medication adherence: staying within the boundaries of safety. Ergonomics. 2018;61(1):82–103.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Bognar K, Everson K, Brauer M, Lakdawalla DN, Forma FM. Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness. Clinicoecon Outcomes Res. 2018;10:573–585.
   PubMed Web of Science ®Google Scholar
• Roebuck MC, Kaestner RJ, Dougherty JS. Impact of medication adherence on health services utilization in Medicaid. Med Care. 2018;56(3):266–273.
   PubMed Web of Science ®Google Scholar
• Broder MS, Greene M, Chang E, Hartry A, Yan T, Yermilov I. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder. J Med Econ. 2019;22(1):63–70.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Leon B, Del Pino-Sedeno T, Serrano-Perez P, Rodriguez Alvarez C, Bejarano-Quisoboni D, Trujillo-Martin MM. Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis. BMC Psychiatry. 2022;22(1):487.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• Mathews SC, McShea MJ, Hanley CL, Ravitz A, Labrique AB, Cohen AB. Digital health: a path to validation. NPJ Digit Med. 2019;2:38.
   PubMed Web of Science ®Google Scholar
• Norgaard M, Ehrenstein V, Vandenbroucke JP. Confounding in observational studies based on large health care databases: problems and potential solutions - a primer for the clinician. Clin Epidemiol. 2017;9:185–193.
   PubMed Web of Science ®Google Scholar
• Ulrich EH, So G, Zappitelli M, Chanchlani R. A review on the application and limitations of administrative health care data for the study of acute kidney injury epidemiology and outcomes in children. Front Pediatr. 2021;9:742888.
   PubMed Web of Science ®Google Scholar
• Joyce GF. Understanding primary nonadherence. Am J Pharm Benefits. 2010;2(2):111–118.
   PubMedGoogle Scholar